Lung Cancer in Never Smokers

Ping Yang

doi:10.1055/s-0031-1272865

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2011; 32(1): 010-021
DOI: 10.1055/s-0031-1272865

Lung Cancer in Never Smokers

Ping Yang¹

¹Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota

Abstract

ABSTRACT

Lung cancer in never smokers (LCINS) has lately been recognized as a unique disease based on rapidly gained knowledge from genomic changes to treatment responses. The focus of this article is on current knowledge and challenges with regard to LCINS expanded from recent reviews highlighting five areas: (1) distribution of LCINS by temporal trends, geographic regions, and populations; (2) three well-recognized environmental risk factors; (3) other plausible environmental risk factors; (4) prior chronic lung diseases and infectious diseases as risk factors; and (5) lifestyles as risk or protective factors. This article will also bring attention to recently published literature in two pioneering areas: (1) histological characteristics, clinical features with emerging new effective therapies, and social and psychological stigma; and (2) searching for susceptibility genes using integrated genomic approaches.

KEYWORDS

Lung cancer - never smokers - environmental risk factors - genetic predisposition - molecular target therapy

Volltext

Referenzen

REFERENCES

1 Subramanian J, Govindan R. Lung cancer in ‘never-smokers’: a unique entity. Oncology (Williston Park). 2010; 24 (1) 29-35
2 Rudin C M, Avila-Tang E, Samet J M. Lung cancer in never smokers: a call to action. Clin Cancer Res. 2009; 15 (18) 5622-5625
3 Samet J M, Avila-Tang E, Boffetta P et al.. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009; 15 (18) 5626-5645
4 Sun S, Schiller J H, Gazdar A F. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007; 7 (10) 778-790
5 Scagliotti G V, Longo M, Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol. 2009; 21 (2) 99-104
6 Lung cancer. http://en.wikipedia.org/wiki/Lung_cancer#cite_note-AUTOREF27-140
7 Morgagni G B. De sedibus et causis morborum per anatomen indagatis. 1761. http://en.wikipedia.org/wiki/Lung_cancer#cite_note-AUTOREF27-140
8 Bayle G L. Recherches sur la phtisie pulmonaire. Paris, France: 1810. http://en.wikipedia.org/wiki/Lung_cancer#cite_ref-AUTOREF28_141-0
9 Fried B M. Primary carcinoma of the lung. Bronchiogenic cancer: a clinical and pathological study. Medicine. 1931; 10 373-508
10 Karsner H T, Saphir O. Small cell carcinomas of the lung. Am J Pathol. 1930; 6 (5) 553-562, 3
11 Weller C V. The pathology of primary carcinoma of the lung. Archives of Pathology. 1929; 7 478-519
12 Rosenblatt M B, Lisa J R. Bronchial adenoma. In: Cancer of the Lung: Pathology, Diagnosis, and Treatment. New York: Oxford University Press; 1956: 259-312
13 United States Surgeon General's Advisory Committee on Smoking and Health .Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: U.S. Department of Health, Education and Welfare, Public Health Service, Government Printing Office; 1964: 19-21
14 Wakelee H A, Chang E T, Gomez S L et al.. Lung cancer incidence in never smokers. J Clin Oncol. 2007; 25 (5) 472-478
15 Johansson M, Relton C, Ueland P M et al.. Serum B vitamin levels and risk of lung cancer. JAMA. 2010; 303 (23) 2377-2385
16 Subramanian J, Morgensztern D, Goodgame B et al.. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010; 5 (1) 23-28
17 National Research Council (NRC) Committee on the Biological Effects of Ionizing Radiations, Board on Radiation Effects Research, Commission on Life Sciences, ed .Health Risks of Radon and Other Internally Deposited Alpha-Emitters: BEIR. Washington: National Academy Press; 1988
18 Harting F, Hesse W. Der Lungenkrebs, die Bergkrankheit in den schneeberger Gruben. Viertel Gerichtl Med Oeff Sanitaetswes. 1879; 31 (102–132) 313-337
19 Samet J M. Indoor radon levels may be higher than in uranium mines. Radon and lung cancer: how great is the risk?. J Respir Dis. 1989; 10 73-83
20 Archer V E, Wagoner J K, Lundin F E. Lung cancer among uranium miners in the United States. Health Phys. 1973; 25 (4) 351-371
21 Samet J M, Kutvirt D M, Waxweiler R J, Key C R. Uranium mining and lung cancer in Navajo men. N Engl J Med. 1984; 310 (23) 1481-1484
22 Gilliland F D, Hunt W C, Archer V E, Saccomanno G. Radon progeny exposure and lung cancer risk among non-smoking uranium miners. Health Phys. 2000; 79 (4) 365-372
23 Al-Zoughool M, Krewski D. Health effects of radon: a review of the literature. Int J Radiat Biol. 2009; 85 (1) 57-69
24 United States Environmental Protection Agency .Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. EPA/600/606–690/006F. Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development; 1992
25 Yang P, Sun Z, Krowka M J et al.. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008; 168 (10) 1097-1103
26 Zatloukal P, Kubík A, Pauk N, Tomásek L, Petruzelka L. Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer. 2003; 41 (3) 283-293
27 Thun M J, Henley S J, Burns D, Jemal A, Shanks T G, Calle E E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006; 98 (10) 691-699
28 National Research Council (NRC), Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, Commission on Life Sciences, ed .Health Effects of Exposure to Radon. (BEIR IV.) Washington. National Academy Press; 1999
29 Lam W K. Lung cancer in Asian women: the environment and genes. Respirology. 2005; 10 (4) 408-417
30 Schmid K, Kuwert T, Drexler H. Radon in indoor spaces: an underestimated risk factor for lung cancer in environmental medicine. Dtsch Arztebl Int. 2010; 107 (11) 181-186
31 Guha N, Merletti F, Steenland N K, Altieri A, Cogliano V, Straif K. Lung cancer risk in painters: a meta-analysis. Environ Health Perspect. 2010; 118 (3) 303-312
32 Harris J M, Johnston I D, Rudd R, Taylor A J, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax. 2010; 65 (1) 70-76
33 Liu Z Y, He X Z, Chapman R S. Smoking and other risk factors for lung cancer in Xuanwei, China. Int J Epidemiol. 1991; 20 (1) 26-31
34 Daniels C E, Jett J R. Does interstitial lung disease predispose to lung cancer?. Curr Opin Pulm Med. 2005; 11 (5) 431-437
35 Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007; 101 (12) 2534-2540
36 Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest. 1995; 108 (5) 1272-1277
37 Yousem S A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990; 21 (5) 467-474
38 Brenner D R, Hung R J, Tsao M S et al.. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer. 2010; 10 285
39 Cheng Y W, Chiou H L, Chen J T et al.. Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan. Lung Cancer. 2004; 46 (2) 165-170
40 Engels E A, Brock M V, Chen J, Hooker C M, Gillison M, Moore R D. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006; 24 (9) 1383-1388
41 Kirk G D, Merlo C, O' Driscoll P et al.. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45 (1) 103-110
42 Laurila A L, Anttila T, Läärä E et al.. Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Int J Cancer. 1997; 74 (1) 31-34
43 Littman A J, White E, Jackson L A et al.. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13 (10) 1624-1630
44 Smith J S, Kumlin U, Nyberg F et al.. Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer. Int J Cancer. 2008; 123 (10) 2469-2471
45 Hinds M W, Cohen H I, Kolonel L N. Tuberculosis and lung cancer risk in nonsmoking women. Am Rev Respir Dis. 1982; 125 (6) 776-778
46 Lim W T, Chuah K L, Leong S S, Tan E H, Toh C K. Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. Oncol Rep. 2009; 21 (4) 971-975
47 Paulus J K, Asomaning K, Kraft P, Johnson B E, Lin X, Christiani D C. Parity and risk of lung cancer in women. Am J Epidemiol. 2010; 171 (5) 557-563
48 Kabat G C, Miller A B, Rohan T E. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer. 2007; 120 (10) 2214-2220
49 Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer. 2005; 117 (4) 662-666
50 Hampton T. Lung cancer mortality higher in women who used combination hormone therapy. JAMA. 2009; 302 (6) 615-616
51 Elliott A M, Hannaford P C. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception. 2006; 73 (4) 331-335
52 Benowitz N L, Lessov-Schlaggar C N, Swan G E, Jacob III P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006; 79 (5) 480-488
53 Key T J, Allen N E, Spencer E A, Travis R C. The effect of diet on risk of cancer. Lancet. 2002; 360 (9336) 861-868
54 World Cancer Research Fund International .Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007
55 Mulder I, Jansen M C, Smit H A Seven Countries Study Research Group et al. Role of smoking and diet in the cross-cultural variation in lung-cancer mortality: the Seven Countries Study. Int J Cancer. 2000; 88 (4) 665-671
56 Liu Y, Sobue T, Otani T, Tsugane S. Vegetables, fruit consumption and risk of lung cancer among middle-aged Japanese men and women: JPHC study. Cancer Causes Control. 2004; 15 (4) 349-357
57 Shimazu T, Inoue M, Sasazuki S Japan Public Health Center-based Prospective Study Group et al. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am J Clin Nutr. 2010; 91 (3) 722-728
58 Leitzmann M F, Koebnick C, Abnet C C et al.. Prospective study of physical activity and lung cancer by histologic type in current, former, and never smokers. Am J Epidemiol. 2009; 169 (5) 542-553
59 Yun Y H, Lim M K, Won Y J et al.. Dietary preference, physical activity, and cancer risk in men: national health insurance corporation study. BMC Cancer. 2008; 8 366
60 Sinner P, Folsom A R, Harnack L, Eberly L E, Schmitz K H. The association of physical activity with lung cancer incidence in a cohort of older women: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2006; 15 (12) 2359-2363
61 Sui X, Lee D C, Matthews C E et al.. Influence of cardiorespiratory fitness on lung cancer mortality. Med Sci Sports Exerc. 2010; 42 (5) 872-878
62 Alberg A J, Ford J G, Samet J M. American College of Chest Physicians . Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132 (3, suppl) 29S-55S
63 Devesa S S, Bray F, Vizcaino A P, Parkin D M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117 (2) 294-299
64 Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health. 1997; 50 (4) 307-364
65 Schneiderman M A, Davis D L, Wagener D K. Lung cancer that is not attributable to smoking. JAMA. 1989; 261 (18) 2635-2636
66 Liam C K, Pang Y K, Leow C H, Poosparajah S, Menon A. Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: experience of a university teaching hospital. Lung Cancer. 2006; 53 (1) 23-30
67 de Andrade M, Ebbert J O, Wampfler J A et al.. Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer. 2004; 43 (2) 127-134
68 Ebbert J O, Chhatwani L, Aubry M C et al.. Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. J Thorac Oncol. 2010; 5 (8) 1213-1220
69 Yang P, Cerhan J R, Vierkant R A et al.. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol. 2002; 156 (12) 1114-1122
70 Raz D J, He B, Rosell R, Jablons D M. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer. 2006; 7 (5) 313-322
71 Laskin J J, Sandler A B, Johnson D H. Redefining bronchioloalveolar carcinoma. Semin Oncol. 2005; 32 (3) 329-335
72 Travis W D, Colby T V, Shimosato Y et al.. Histological Typing of Lung and Pleural Tumours. 3rd ed. New York: Springer-Verlag; 1999: 21-47
73 Gao P, Yang X, Xue Y W et al.. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer. 2009; 115 (14) 3222-3232
74 Kubo T, Yamamoto H, Ichimura K et al.. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer. 2009; 65 (3) 328-332
75 Rusch V W, Reuter V E, Kris M G et al.. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg. 1992; 104 (5) 1465-1469
76 Marchetti A, Buttitta F, Pellegrini S et al.. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol. 1996; 179 (3) 254-259
77 Holst V A, Finkelstein S, Yousem S A. Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol. 1998; 22 (11) 1343-1350
78 Yamasaki M, Takeshima Y, Fujii S, Matsuura M, Tagawa K, Inai K. Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung. Pathol Int. 2000; 50 (11) 891-896
79 Yamasaki M, Takeshima Y, Fujii S et al.. Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathol Int. 2000; 50 (10) 778-785
80 Gandara D R, West H, Chansky K et al.. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004; 10 (12 Pt 2) 4205s-4209s
81 Wislez M, Beer D G, Wistuba I, Cadranel J, Saijo N, Johnson B E. Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol. 2006; 1 (9, suppl) S8-S12
82 Sakuma Y, Matsukuma S, Yoshihara M et al.. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol. 2007; 20 (9) 967-973
83 Dacic S, Sasatomi E, Swalsky P A, Kim D W, Finkelstein S D, Yousem S A. Loss of heterozygosity patterns of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicate a similar molecular pathogenesis. Arch Pathol Lab Med. 2004; 128 (8) 880-884
84 Toonkel R L, Borczuk A C, Powell C A. TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol. 2010; 5 (2) 153-157
85 Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. Arch Pathol Lab Med. 2010; 134 (1) 66-72
86 Ahn M J, Lee J, Park Y H et al.. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol. 2010; 5 (8) 1185-1196
87 Kawaguchi T, Matsumura A, Fukai S et al.. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol. 2010; 5 (7) 1001-1010
88 Kawaguchi T, Takada M, Kubo A et al.. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010; 5 (5) 620-630
89 Meguid R A, Hooker C M, Harris J et al.. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest. 2010; 138 (3) 500-509
90 Riely G J. Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology (Williston Park). 2010; 24 (1) 38-40
91 Doran E, Jackman D. Fire without smoke: lung cancer in 'never-smokers'. Oncology (Williston Park). 2010; 24 (1) 40-43
92 Burns T F, Rudin C M. Lung cancer in ‘never-smokers’: beyond EGFR mutations and EGFR-TK inhibitors. Oncology (Williston Park). 2010; 24 (1) 48-49
93 Kawaguchi T, Takada M, Kubo A et al.. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol. 2010; 5 (7) 1011-1017
94 Jian G, Songwen Z, Ling Z et al.. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010; 136 (9) 1341-1347
95 Faehling M, Eckert R, Kuom S, Kamp T, Stoiber K M, Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology. 2010; 78 (3–4) 249-258
96 Reck M. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Rev Anticancer Ther. 2010; 10 (6) 955-965
97 Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010; 11 (8) 1343-1357
98 Kono S A, Marshall M E, Ware K E, Heasley L E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat. 2009; 12 (4–5) 95-102
99 Eisenhauer E A, Therasse P, Bogaerts J et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2) 228-247
100 Jackman D, Pao W, Riely G J et al.. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28 (2) 357-360
101 Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br J Cancer. 2007; 96 (6) 857-863
102 Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka-Akita H, Nishimura M. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer. 2006; 54 (3) 419-422
103 Marchetti A, Milella M, Felicioni L et al.. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia. 2009; 11 (10) 1084-1092
104 Rho J K, Choi Y J, Lee J K et al.. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res. 2009; 7 (10) 1736-1743
105 Chen H J, Mok T S, Chen Z H et al.. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009; 15 (4) 651-658
106 Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010; 30 (7) 2513-2517
107 Zhang W, Stabile L P, Keohavong P et al.. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol. 2006; 1 (7) 635-647
108 Kook E H, Kim Y M, Kim H T et al.. Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib. Oncol Res. 2010; 18 (9) 445-451
109 Ullrich R T, Zander T, Neumaier B et al.. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS ONE. 2008; 3 (12) e3908
110 Wong M K, Lo A I, Lam B, Lam W K, Ip M S, Ho J C. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol. 2010; 65 (6) 1023-1028
111 Costa D B, Nguyen K S, Cho B C et al.. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008; 14 (21) 7060-7067
112 Kuo C H, Lin S M, Lee K Y et al.. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer. 2010; 11 (1) 51-56
113 Manson G V, Ma P C. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. Clin Lung Cancer. 2010; 11 (1) 57-60
114 Tang Z, Du R, Jiang S et al.. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008; 99 (6) 911-922
115 Regales L, Gong Y, Shen R et al.. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009; 119 (10) 3000-3010
116 Sawai A, Chandarlapaty S, Greulich H et al.. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 2008; 68 (2) 589-596
117 Kim J E, Lee D H, Choi Y et al.. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65 (3) 351-354
118 Olmez I, Donahue B R, Butler J S, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010; 70 (2) 174-179
119 Lee Y J, Shim H S, Kang Y A et al.. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol. 2010; 136 (12) 1937-1944
120 Soda M, Choi Y L, Enomoto M et al.. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448 (7153) 561-566
121 Sasaki T, Rodig S J, Chirieac L R, Jänne P A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46 (10) 1773-1780
122 Zhang X, Zhang S, Yang X et al.. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010; 9 188
123 Takahashi T, Sonobe M, Kobayashi M et al.. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17 (3) 889-897
124 Shaw A T, Yeap B Y, Mino-Kenudson M et al.. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27 (26) 4247-4253
125 Yang P, Oliveira A, Wampfler J et al.. Reduced disease-free survival associated with anaplastic lymphoma kinase translocation (ALK + ) in lung adenocarcinoma patients with no cigarette smoking history. Paper presented at: American Society for Radiation Oncology; December 9–10, 2010; Chicago, IL
126 Neal J W, Sequist L V. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol. 2010; 11 (1–2) 36-44
127 Raleigh Z T. A biopsychosocial perspective on the experience of lung cancer. J Psychosoc Oncol. 2010; 28 (1) 116-125
128 Gorlova O Y, Weng S F, Zhang Y, Amos C I, Spitz M R. Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer. 2007; 121 (1) 111-118
129 Broderick P, Wang Y, Vijayakrishnan J et al.. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009; 69 (16) 6633-6641
130 Bailey-Wilson J E, Amos C I, Pinney S M et al.. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004; 75 (3) 460-474
131 Amos C I, Pinney S M, Li Y et al.. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res. 2010; 70 (6) 2359-2367
132 You M, Wang D, Liu P et al.. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res. 2009; 15 (8) 2666-2674
133 Wang M, Vikis H G, Wang Y et al.. Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1 Cancer Res. 2007; 67 (1) 93-99
134 Amos C I, Wu X, Broderick P et al.. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 Nat Genet. 2008; 40 (5) 616-622
135 Hung R J, McKay J D, Gaborieau V et al.. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008; 452 (7187) 633-637
136 Liu P, Vikis H G, Wang D et al.. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008; 100 (18) 1326-1330
137 McKay J D, Hung R J, Gaborieau V EPIC Study et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008; 40 (12) 1404-1406
138 Rafnar T, Sulem P, Stacey S N et al.. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet. 2009; 41 (2) 221-227
139 Spitz M R, Amos C I, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008; 100 (21) 1552-1556
140 Thorgeirsson T E, Geller F, Sulem P et al.. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008; 452 (7187) 638-642
141 Wang Y, Broderick P, Webb E et al.. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008; 40 (12) 1407-1409
142 Yang P, Li Y, Jiang R et al.. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19 (1) 240-244
143 Li Y, Sheu C C, Ye Y et al.. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010; 11 (4) 321-330
144 Landi M T, Chatterjee N, Caporaso N E et al.. GPC5 rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol. 2010; 11 (8) 714-716
145 Yang P, Jen J, Li Y et al.. Lancet Oncol. 2010; 11 716, authors' reply
146 Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics. 1997; 40 (1) 24-30
147 Blackhall F H, Merry C L, Davies E J, Jayson G C. Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001; 85 (8) 1094-1098
148 Yang P, Ebbert J O, Sun Z, Weinshilboum R M. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol. 2006; 24 (11) 1761-1769
149 Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer. 2003; 107 (1) 139-144
150 Bennett W P, Alavanja M C, Blomeke B et al.. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst. 1999; 91 (23) 2009-2014
151 Weinberg C R, Sandler D P. Gene-by-environment interaction for passive smoking and glutathione S-transferase M1?. J Natl Cancer Inst. 1999; 91 (23) 1985-1986
152 Nyberg F, Hou S M, Hemminki K, Lambert B, Pershagen G. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev. 1998; 7 (10) 875-883
153 Zhou W, Liu G, Miller D P et al.. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12 (4) 359-365
154 Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 2005; 223 (2) 219-226
155 Cohet C, Borel S, Nyberg F et al.. Exon 5 polymorphisms in the O6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol Biomarkers Prev. 2004; 13 (2) 320-323
156 Vogel U, Christensen J, Wallin H et al.. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008; 639 (1-2) 89-100
157 Olivo-Marston S E, Yang P, Mechanic L E et al.. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18 (12) 3375-3383
158 Shen M, Vermeulen R, Rajaraman P et al.. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen. 2009; 50 (4) 285-290
159 Lee K M, Shen M, Chapman R S et al.. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis. 2007; 28 (7) 1437-1441
160 Wang L I, Neuberg D, Christiani D C. Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med. 2004; 46 (6) 556-564
161 Senn O, Russi E W, Imboden M, Probst-Hensch N M. alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J. 2005; 26 (5) 909-917

Ping YangM.D.

Department of Health Sciences Research, College of Medicine

Mayo Clinic, 200 First St. SW, Rochester, MN 55905

eMail: yang.ping@mayo.edu